SC
ACHL

Stempoint Capital’s Achilles Therapeutics ACHL Stock Holding History

Stempoint Capital’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,385,750
Closed -$1.73M – 78
2024
Q1 		$1.73M Buy
+1,385,750
New +$1.49M 0.46% 40

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Stempoint Capital's ACHL Position: Q2 2024 in Review

Stempoint Capital sold out of Achilles Therapeutics (ACHL) in Q2 2024, closing a stake of 1,385,750 shares — an estimated $1.73M sold.

Stempoint Capital first reported a position in ACHL in Q1 2024 and held it in 1 quarter. The position peaked at $1.73M in Q1 2024. 27 funds tracked by Wall St. Rank hold ACHL as of Q2 2024.

  • Stempoint Capital reported no remaining Achilles Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Stempoint Capital sold 1,385,750 Achilles Therapeutics shares in Q2 2024, an estimated $1.73M.
  • Stempoint Capital first reported a position in Achilles Therapeutics in Q1 2024 and held it in 1 quarter.
  • Stempoint Capital's Achilles Therapeutics position peaked at $1.73M in Q1 2024.
  • 27 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q2 2024.

Based on Stempoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.